Gilead Sciences (GILD) Cash & Equivalents Growth (1y) (2010 - 2026)
Gilead Sciences (GILD) Cash & Equivalents Growth (1y) (2010 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Cash & Equiv. Growth (1y) (Qtr) |
| 1 |
Gsk |
93,699,046.73 Bn |
93,699,041.77 Bn |
7.76 Bn |
-17.47% |
| 2 |
Eli Lilly |
1,012.06 Bn |
1,006.77 Bn |
16.22 Bn |
70.76% |
| 3 |
Johnson & Johnson |
560.67 Bn |
538.62 Bn |
15.96 Bn |
-43.63% |
| 4 |
AbbVie |
402.20 Bn |
392.85 Bn |
10.78 Bn |
81.47% |
| 5 |
Merck |
298.59 Bn |
292.94 Bn |
12.09 Bn |
-38.27% |
| 6 |
Amgen |
188.77 Bn |
176.74 Bn |
5.87 Bn |
36.64% |
| 7 |
Gilead Sciences |
160.22 Bn |
152.49 Bn |
5.52 Bn |
-3.76% |
| 8 |
Pfizer |
148.19 Bn |
135.42 Bn |
-1.21 Bn |
19.09% |
| 9 |
Bristol Myers Squibb |
116.72 Bn |
106.26 Bn |
8.07 Bn |
-11.96% |
| 10 |
Novartis Ag |
109.78 Bn |
109.09 Bn |
- |
- |
| Date | Value |
|---|
| Mar 31, 2026 |
-3.76% |
| Dec 31, 2025 |
-24.29% |
| Sep 30, 2025 |
45.52% |
| Jun 30, 2025 |
85.57% |
| Mar 31, 2025 |
67.99% |
| Dec 31, 2024 |
64.19% |
| Sep 30, 2024 |
-11.71% |
| Jun 30, 2024 |
-51.40% |
| Mar 31, 2024 |
-4.42% |
| Dec 31, 2023 |
12.44% |
| Sep 30, 2023 |
21.41% |
| Jun 30, 2023 |
20.36% |
| Mar 31, 2023 |
14.90% |
| Dec 31, 2022 |
1.39% |
| Sep 30, 2022 |
7.73% |
| Jun 30, 2022 |
-3.15% |
| Mar 31, 2022 |
5.68% |
| Dec 31, 2021 |
-10.99% |
| Sep 30, 2021 |
-66.15% |
| Jun 30, 2021 |
-27.47% |
